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5Departamento de Bioquı́mica y Bioloǵıa Molecular y Celular, Facultad de Veterinaria, Universidad de Zaragoza,
Zaragoza, Spain
Correspondence should be addressed to Roberto Mart́ınez-Beamonte; romartin@unizar.es
Received 18 February 2020; Accepted 16 September 2020; Published 15 December 2020
Copyright © 2020 Roberto Mart́ınez-Beamonte et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The liver is an essential metabolic organ which governs body
energy metabolism connected with adipose tissue and
skeletal muscle among other tissues. The prevalence of
obesity has reached epidemic proportions in many countries
around the world and continues to grow every year which is
caused by multiple factors, with diet and lifestyle being the
most researched and therefore most important.
Nonalcoholic fatty liver disease (NAFLD) is one of the
several metabolic complications associated with obesity. The
pathology of NAFLD is difficult to recognize or diagnose
especially in early stages without a biopsy and therefore can
remain undetected for significant time allowing the disease
to progress.
The diagnosis of NAFLD is crucial to be able to start
adequate treatment including changes in diet and lifestyle in
the first stage of the disease when the pathology is reversible
and prevent the development of severe forms of the disease
such as nonalcoholic steatohepatitis (NASH) or the irre-
versible cirrhosis stage.
When the liver becomes damaged, this can lead to some
metabolic alterations that have a severe and multifaceted
impact in type 2 diabetes mellitus (T2DM), visceral obesity,
and cardiovascular disease related to elevated plasmatic
cholesterol, triglycerides, transaminases, and others that
indicate hepatic disorders and oxidative stress.
This special issue aims to bring articles to assemble the
latest progress to combat NAFLD, NASH, and cirrhosis
mainly related to overweight and obesity which are in-
creasingly prevalent in today’s society. The manuscripts
received by the journal were carefully selected pursuing this
objective.
I. Grgurevic et al.’s review paper “Natural History of
Nonalcoholic Fatty Liver Disease: Implications for Clinical
Practice and an Individualized Approach” summarizes the
current knowledge on the natural history of NAFLD and
suggests there is not still strong evidence of significant as-
sociation between the inflammatory component of NAFLD
and the adverse clinical outcomes. The authors propose
older age (>50 years) and presence of T2DM and some
genetic variants as indicators of increased risk of having liver
fibrosis.
The review made by Z. Miao et al. showed new insights
and basis for medical therapy on adipose metabolic diseases,
related to diet, and more concrete with the consumption of
vitamin D. This review summarized the relationship between
vitamin D and the adipose tissue that represent the major
storage of vitamin D and classified its biological roles and
functionalities with the regulation and development on
adipogenesis and other metabolic diseases, calcium ho-
meostasis, and energy metabolism.
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H. Ou et al. have written a cross-sectional study with 225
patients with NAFLD, smokers, and nonsmokers, to evaluate
a lifestyle parameter over NAFLD. Liver-significant fibrosis
was diagnosed by liver stiffness using a FibroScan. The re-
sults indicate that the risk of fibrosis in smokers with
NAFLD is significantly higher, showing higher changes in
significant liver fibrosis and advanced liver fibrosis in these
patients, with influence of age and AST levels too.
T. Himoto et al. made a cross-sectional study with diet
intervention during 6 months in patients with NAFLD to
determine the nutritional and dietary factors associated with
muscle volume loss in these patients with presarcopenia,
sarcopenia, and sarcopenic obesity. The authors indicate that
there are different factors that regulate muscle volume loss in
male and female NAFLD patients.
Another interesting paper written by B. Mart́ınez et al.
used a special diet during 2 months in a porcine animal
model to induce fatty liver. After the dietary fatty liver
induction, the authors used 10 mg/kg/day of melatonin to
reverse the fatty liver, feeding the animals with the same
steatosic special diet. The results showed that the melatonin
group does not increase steatosis, with a decrease of MDA
levels.
A. M. Akinnuga et al. presented the first work using
bredemolic acid in a diet-induced prediabetic rat model
during 12 weeks. The prediabetes model showed an increase
in AST and ALT, liver glycogen and triglycerides, and lipid
peroxidation and a decrease in SREBP1 expression. The
bredemolic acid administration decreased liver enzyme
concentration and hepatic oxidative stress and improved
antioxidant enzymes such as SOD and GPx, thus improving
liver function.
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